Jens Kollmeier

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer

Daniel G. Weber, Georg Johnen, Swaantje Casjens et al. · BMC Research Notes · 2013 · 194 citations · Full text

Medicine, Molecular Biology, Oncology +17

The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study

Christian Boch, Jens Kollmeier, Andreas Röth et al. · BMJ Open · 2013 · 153 citations · Full text

Medicine, Genetics, Oncology +16

Morphometrical analysis of transbronchial cryobiopsies

Sergej Griff, Wim Ammenwerth, Nicolas Schönfeld et al. · Diagnostic Pathology · 2011 · 132 citations · Full text

Medicine, Pathology, Histology +12

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study

Michael Kreuter, Johan Vansteenkiste, J.R. Fischer et al. · Annals of Oncology · 2012 · 89 citations · Full text

Medicine, Oncology, Pharmacology +11